Vanguard Group Inc Arcus Biosciences, Inc. Transaction History

Vanguard Group Inc

$5.57 Trillion
Q4 2024

A detailed history of Vanguard Group Inc transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 5,389,216 shares of RCUS stock, worth $51.6 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

5,389,216

Previous 5,468,755 1.45%

Holding current value

$51.6 Million

Previous $83.6 Million 4.03%

% of portfolio

0.0%

Previous 0.0%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 11, 2025	SELL	$14.28 - $18.44 $1.14 Million - $1.47 Million	-79,539 Reduced 1.45%	5,389,216 $80.2 Million
Q3 2024 Nov 13, 2024	BUY	$13.69 - $18.01 $2.89 Million - $3.81 Million	211,429 Added 4.02%	5,468,755 $83.6 Million
Q2 2024 Aug 13, 2024	BUY	$14.59 - $18.48 $6.8 Million - $8.61 Million	466,082 Added 9.73%	5,257,326 $80.1 Million
Q1 2024 May 10, 2024	BUY	$14.83 - $20.18 $1.64 Million - $2.23 Million	110,528 Added 2.36%	4,791,244 $90.5 Million
Q4 2023 Feb 14, 2024	BUY	$13.43 - $19.63 $2.51 Million - $3.67 Million	186,898 Added 4.16%	4,680,716 $89.4 Million
Q3 2023 Nov 14, 2023	BUY	$17.62 - $23.54 $1.08 Million - $1.44 Million	61,040 Added 1.38%	4,493,818 $80.7 Million
Q2 2023 Aug 14, 2023	BUY	$16.97 - $22.03 $154,749 - $200,891	9,119 Added 0.21%	4,432,778 $90 Million
Q1 2023 May 15, 2023	BUY	$15.96 - $23.15 $805,692 - $1.17 Million	50,482 Added 1.15%	4,423,659 $80.7 Million
Q4 2022 Feb 10, 2023	SELL	$19.7 - $35.71 $1.65 Million - $3 Million	-84,007 Reduced 1.88%	4,373,177 $90.4 Million
Q3 2022 Nov 14, 2022	BUY	$23.23 - $30.07 $4.04 Million - $5.23 Million	173,854 Added 4.06%	4,457,184 $117 Million
Q2 2022 Aug 12, 2022	BUY	$17.23 - $37.73 $13.3 Million - $29.1 Million	771,216 Added 21.96%	4,283,330 $109 Million
Q1 2022 May 13, 2022	BUY	$28.92 - $41.83 $2.48 Million - $3.59 Million	85,778 Added 2.5%	3,512,114 $111 Million
Q4 2021 Feb 14, 2022	BUY	$31.38 - $48.47 $30.1 Million - $46.5 Million	959,857 Added 38.92%	3,426,336 $139 Million
Q3 2021 Nov 12, 2021	BUY	$26.93 - $37.68 $996 - $1,394	37 Added 0.0%	2,466,479 $86 Million
Q2 2021 Aug 13, 2021	BUY	$22.75 - $35.77 $56.1 Million - $88.2 Million	2,466,442 New	2,466,442 $67.7 Million

Others Institutions Holding RCUS

# of Institutions

201

Shares Held

51.2M

Call Options Held

288K

Put Options Held

138K

View Full List

About Arcus Biosciences, Inc.

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $691M
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

More about RCUS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Arcus Biosciences, Inc. Transaction History